Hemophilia A is an X-linked, recessive, bleeding disorder caused by a deficienty in the activity of coagulation Factor VIII. Affected individuals develop a variable phenotype of hemorrhage into joints and muscles, easy bruising, and prolonged bleeding from wounds. The disorder is caused by heterogeneous mutations in the Factor VIII gene. Up to 30% of hemophilia A patients given therapeutic Factor VIII can make inhibitory antibodies, the majority of which are reactive with its C2 and A2 domains
Applications:
Suitable for use in ELISA and Western Blot. Other applications not tested.
Recommended Dilution:
Optimal dilutions to be determined by the researcher.
Hybridoma:
NS1 myeloma cells with spleen cells from Balb/c mice.
Storage and Stability:
Lyophilized powder may be stored at -20 degrees C. Reconstitute with sterile 40-50% glycerol, aliquot and store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.